Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39241743.
- Also identified by DOI 10.1016/j.cell.2024.07.056.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al.<sup>1</sup> report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.
Medical subject headings
- Autoimmune Diseases
- Receptors, Chimeric Antigen